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ABSTRACT 
RNA binding motif protein 20 (RBM20) is a key regulator of alternative splicing in the heart, and its mutation 
leads to malignant dilated cardiomyopathy (DCM). To understand the mechanism of RBM20-associated DCM, 
we engineered isogenic human induced pluripotent stem cells (iPSCs) with heterozygous or homozygous 
DCM-associated missense mutations in RBM20 (R636S) as well as RBM20 knockout (KO) iPSCs. iPSC-
derived engineered heart tissues made from these cell lines recapitulated contractile dysfunction of RBM20-
associated DCM and revealed greater dysfunction with missense mutations than KO. Analysis of RBM20 RNA 
binding by eCLIP revealed a gain-of-function preference of mutant RBM20 for 3′ UTR sequences that are 
shared with amyotrophic lateral sclerosis (ALS) and processing-body associated RNA binding proteins (FUS, 
DDX6). Deep RNA sequencing revealed that the RBM20 R636S mutant has unique gene, splicing, 
polyadenylation and circular RNA defects that differ from RBM20 KO, impacting distinct cardiac signaling 
pathways. Splicing defects specific to KO or R636S mutations were supported by data from R636S gene-
edited pig hearts and eCLIP. Super-resolution microscopy verified that mutant RBM20 maintains limited 
nuclear localization potential; rather, the mutant protein associates with cytoplasmic processing bodies (DDX6) 
under basal conditions, and with stress granules (G3BP1) following acute stress. Taken together, our results 
highlight a novel pathogenic mechanism in cardiac disease through splicing-dependent and -independent 
pathways that are likely to mediate differential contractile phenotypes and stress-associated heart pathology. 
  
INTRODUCTION 
Dilated cardiomyopathy (DCM) is the most common indication for heart transplantation (McNally and Mestroni, 
2017; Virani et al., 2021; Schultheiss et al., 2019). Recent insights into the genetics of DCM have revealed over 
fifty DCM causal genes that involve a wide variety of cellular processes and represent high priority targets for 
precision therapies (Schultheiss et al., 2019; McNally et al., 2013).  These studies have expanded the scope of 
cardiomyopathy research well beyond cardiac energetics, conduction, or contractility (Jefferies and Towbin, 
2010; Seidman and Seidman, 2011; McNally and Mestroni, 2017; Schultheiss et al., 2019; Norton et al., 2012). 
In particular, accumulating evidence implicates defects in RNA splicing and protein quality control in heart failure 
pathogenesis (Maatz et al., 2014; Rindler et al., 2017; Xu et al., 2005; Ding et al., 2004; Kong et al., 2010; 
Torrado et al., 2010). Indeed, DCM can be caused by mutation or dysregulation of multiple splicing factors 
(Anderson et al., 1995; Verma et al., 2013). Because the altered regulation of a single splicing factor can impact 
broad splicing regulatory networks, the effect of splicing factor mutations is multifaceted, leading to disruption of 
many cardiac signaling, transcriptional, and structural pathways.  
 
The RNA binding motif protein 20 (RBM20) is a splicing regulator primarily expressed in heart and skeletal 
muscle, where it plays a central role in cardiac physiology. RBM20 directly binds to the primary RNA (pre-
mRNAs) of many cardiomyopathy-associated genes where, by a process of exon exclusion, it ensures the proper 
production of adult protein isoforms (i.e., splice isoforms associated with cardiac maturation) (Maatz et al., 2014; 
Beraldi et al., 2014; Guo et al., 2012; Brauch et al., 2009; Wells et al., 2013). Autosomal dominant mutations in 
RBM20 account for up to 3% of DCM cases (Emig et al., 2010; Wells et al., 2013; Maatz et al., 2014). Further, 
RBM20 DCM is highly penetrant, is associated with life-threatening ventricular arrhythmias, and displays earlier 
age of onset than DCM associated with mutations in other proteins (e.g., laminA/C or Titin). RBM20 DCM 
missense mutations are enriched in a stretch of five amino acids (RSRSP, which contains the R636S mutation) 
in the arginine-serine-rich (RS) domain of the protein (Brauch et al., 2009; Emig et al., 2010). Surprisingly, 
nonsense mutations or missense mutations in other portions of the 1227-amino acid-long protein are relatively 
rare, suggesting that they are either undiagnosed due to a mild phenotype or not tolerated (Emig et al., 2010; 
Refaat et al., 2012). 
 
Wild-type RBM20 has been shown to repress exon inclusion in key regulators of cardiac excitation-contraction 
coupling such as TTN, CAMK2D and RYR2, through binding to a UCUU consensus motif in adjacent introns 
(Maatz et al., 2014) . Isolated cardiomyocytes (CMs) from rodents lacking RBM20 demonstrate prolonged action 
potentials and striking calcium handling defects including increased calcium transit amplitude, increased 
sarcoplasmic reticulum and diastolic calcium levels, and spontaneous calcium sparks (van den Hoogenhof et 
al., 2018). While loss of RBM20 expression leads to DCM, cardiac fibrosis, sudden death and arrhythmias in 
rodent models, few studies have focused on the precise role of mutant forms of the protein that correspond to 
human disease (van den Hoogenhof et al., 2018; Guo et al., 2012). Crucially, direct analysis of RBM20 RNA 
binding sites by CLIP (cross-linking immunoprecipitation) sequencing approaches has only been performed in 
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wild-type (WT) rodent CMs and HEK293 cells (Maatz et al., 2014), thus whether mutant and wild-type RBM20 
have distinct RNA binding preferences remains unclear.  
 
Studies of the effect of pathogenic RBM20 mutants have spanned human, cell and animal models. Analyses of 
resected human DCM hearts from individuals carrying RBM20 mutations (R636S or S635A) have identified 
intriguing global differences in splice-isoform and circular RNA expression, which are associated with the 
regulation of cardiac contractility (Guo et al., 2012; Maatz et al., 2014). CM differentiation of human induced 
pluripotent stem cells (iPSCs) harboring pathological forms of RBM20 has identified calcium handling defects 
and splicing defects previously observed in rodent knockout (KO) models (Streckfuss-Bömeke et al., 2017; 
Wyles et al., 2016; van den Hoogenhof et al., 2018; Guo et al., 2012). In an impressive recent effort, pigs were 
engineered with either heterozygous (HTZ) or homozygous (HMZ) R636S mutations in RBM20 (Schneider et 
al., 2020). This model led to three crucial observations: 1) RBM20 R636S HMZ mutation leads to highly penetrant 
neonatal lethality due to heart failure; 2) mutant RBM20 co-localizes with stress granules in the CM cytoplasm 
after metabolic stress induced by sodium arsenate; and 3) RBM20 undergoes an apparent liquid-liquid phase 
separation. However, these studies raised intriguing questions regarding the role of RBM20 in pathogenesis, 
physiology, normal cardiac development and downstream RNA biology.  
 
To address these questions, we used genome editing to generate an allelic series of RBM20 mutants, including 
one of the point mutations in the RS domain, R636S, as well as a RBM20 KO, in human iPSCs from a healthy 
subject. Normal splice patterns were differentially perturbed in RBM20 mutants as compared to KO, and 
genome-wide profiling of RBM20-RNA interactions revealed that mutant RBM20 showed a preference for the 3’ 
UTR of mRNAs. We observed co-localization of mutant RBM20 with cytoplasmic processing bodies, sites of 
mRNA storage and turnover, and with the canonical stress granule marker G3BP1 specifically following acute 
stress induction. Functional characterization of RBM20 R636S heterozygote 3D engineered heart tissues (EHTs) 
recapitulated aspects of DCM, providing a powerful model system. Collectively, our results indicate both splicing-
dependent and splicing-independent mechanisms for RBM20 DCM pathogenesis, and suggest that RS domain 




Engineering iPSC-CMs with the RBM20 R636S mutation or RBM20 knockout 
To model RBM20 cardiomyopathy mutants within iPSC-CMs, we selected a commonly occurring RS domain 
RBM20 missense mutation: R636S (DNA: C1906A) (Brauch et al., 2009). The heterozygous mutation (R636S 
HTZ) was introduced into iPSCs derived from a healthy male subject (WTC11) using transcription activator-like 
effector nucleases (TALENs) and a droplet digital PCR (ddPCR) based strategy (Figs. 1A, B) (Miyaoka et al., 
2016, 2014). To create HMZ R636S mutant iPSCs, we retargeted the WT allele of the R636S HTZ iPSC line 
using an allele-specific sgRNA together with dual Cas9 nickases to create an allele with the R636S mutation and 
a silent mutation (T1905A) that distinguishes the newly created R636S plus silent mutation (SM) allele from the 
original WT and R636S alleles (R636S HMZ; Fig. 1B and Figs. S1A-C). To compare the R636S mutation with 
a loss-of-function mutation, we utilized our previously generated WTC11 iPSC line with an RBM20 HMZ 8-bp 
deletion (1917-1924del; RBM20 KO) (Fig. 1C) (Miyaoka et al., 2016). We confirmed that these cell lines 
maintained the normal male karyotype as well as loss of RBM20 protein in KO iPSC-CMs by immunofluorescent 
staining (Extended Data Figs. 1D-F) (Miyaoka et al., 2016). Importantly, we were able to generate iPSC-CMs 
from RBM20 mutants of high purity in all four cell lines (Extended Data Fig. 1G). 
 
R636S mutant iPSC-CMs exhibit electrophysiological and contractile abnormalities 
Approximately 30% and 44% of RBM20 DCM patients display conduction system disorders and malignant 
ventricular arrhythmias, respectively. To test whether RBM20 mutant iPSC-CMs display electrophysiological 
aberrations, we used multi-electrode arrays (MEAs) to record their spontaneous field potential changes (Fig. 1D 
and Extended Data Video 1). While we observed some biological variability across different iPSC-CM batches, 
the trends between biological replicates were consistent (Fig. 1D). Field potential duration corrected for beat 
rate differences (FPDc), an in vitro surrogate of the QT interval and biomarker for arrhythmogenesis risk (Blinova 
et al., 2018), was not altered in RBM20 mutants. Beat rate was non-significantly reduced in RBM20 KO cells (p 
= 0.09), and RBM20 R636S HTZ iPSC-CMs displayed a statistically significant increase in spike amplitude, while 
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RBM20 KO iPSC-CMs displayed a decrease in spike amplitude (Fig. 1D). In addition, conduction velocity was 
significantly decreased specifically in RBM20 KO iPSC-CMs (Fig. 1D). 
  
The hallmark of RBM20 DCM is decreased cardiac contractility. To assess cardiac contractility in RBM20 mutant 
iPSC-CMs, we generated three-dimensional engineered heart tissues (3D-EHTs), an established model to 
promote iPSC-CM maturation closer to adult-like myocardium and perform more predictive disease modelling 
experiments (Fig. 1E and Extended Data Videos 2, 3) (Ronaldson-Bouchard et al., 2019; Campostrini et al., 
2021; Karbassi et al., 2020; Leonard et al., 2018). Importantly, to ensure comparability across conditions we 
enriched hiPSC-CMs to >90% purity through metabolic selection with sodium lactate prior to 3D-EHT casting 
(Extended Data Fig. 1G). RBM20 R636S HTZ and HMZ 3D-EHTs displayed significantly decreased force 
generation and upstroke velocity, recapitulating aspects of DCM (Fig. 1F). Intriguingly, RBM20 KO 3D-EHTs 
demonstrated a less dramatic decrease than the RBM20 point mutations in both these parameters and were not 
significantly altered compared to WT controls (Fig. 1F). These data are in line with a recent report indicating that 
RBM20 KO mice have normal cardiac contractility (Ihara et al., 2020). Collectively, these electrophysiology and 
contractility analyses demonstrate distinct functional effects of RBM20 missense and nonsense mutation, 
suggesting that R636S may be a gain-of-function mutation.  
 
RBM20 is mis-localized in R636S mutant iPSC-CMs 
To better understand the cellular mechanisms underlying the DCM-like phenotypes in R636S mutant HTZ and 
HMZ iPSC-CMs, we examined intracellular localization of the mutant protein. RBM20 is known to localize to the 
nucleus, where it forms discrete foci that exquisitely co-localize with the site of TTN transcription (Bertero et al., 
2019). However, several groups have demonstrated that both RSRSP deletion mutants and DCM point 
mutations within the RSRSP stretch, including the R636S mutation, result in mis-localization of overexpressed 
(exogenous) RBM20 from the nucleus to the cytoplasm (Ihara et al., 2020; Schneider et al., 2020; Filippello et 
al., 2013; Murayama et al., 2018; Sun et al., 2020; Gaertner et al., 2020). Confocal analyses indicated that 
endogenous RBM20 in WT iPSC-CMs localized to the nucleus and was enriched in prominent foci (usually two 
per nucleus, as immature iPSC-CMs are generally diploid), while R636S HTZ and R636S HMZ iPSC-CMs 
displayed more numerous and smaller RBM20 puncta which appeared primarily cytoplasmic (Fig. 2A). To 
assess this aspect more robustly and exclude any potential artifact of maximum intensity image visualization of 
diffraction-limited microscopy, we turned to structured illumination microscopy (SIM), which affords a ~2x 
increase in both lateral and axial resolution compared to conventional techniques (e.g., confocal and wide-field; 
Fig. 2B) (Gustafsson, 2005, 2000; Heintzmann and Gustafsson, 2009). 3D axial projections of SIM data 
confirmed that RBM20 in R636S HTZ and HMZ iPSC-CMs was present in both the nucleus and cytoplasm, with 
a majority of RBM20 in R636S HMZ cells localized to the cytoplasm (Fig. 2B, C). These results indicate that 
contrary to previous reports, the exclusion of mutant RBM20 from the nucleus is not complete.  
 
R636S and WT RBM20 mediate distinct mRNA interactions 
To define the molecular mechanisms underlying R636S-associated defects leading to DCM, we performed an 
unbiased survey of direct targets for WT and mutant RBM20 binding using enhanced cross-linking 
immunoprecipitation sequencing (eCLIP) (Fig. 3A and Extended Data Fig. 2A) (Van Nostrand et al., 2016). 
RBM20 eCLIP of WT iPSC-CMs identified 1,240 reproducible peaks in biological replicates corresponding to 
204 genes, including numerous well-established RBM20 splicing targets (e.g., TTN, CAMK2D, RYR2, LDB3, 
LMO7, LRRFIP1, MLIP, OBSCN, SORBS2, TNN2) (Extended Data Table 1, 2). Notably, these include prior 
presumed RBM20 direct targets not previously evidenced in rat heart HITS-CLIP (CAMK2D, OBSCN, LDB3) 
(Maatz et al., 2014). In addition, this analysis identified a number of novel RBM20 targets including ion channels 
(CACNA1C, KCNIP4, KCNQ5, SLC8A1), RNA binding proteins (RBM20, FUS, QKI, FUBP3), lncRNAs and other 
cardiac regulatory factors (e.g., MYOCD, CTNNB1, HAND2, MYH6, SPATS2, GSE1, GNAI3, TPM1). Consistent 
with the literature, WT RBM20 bound principally to intronic elements, and was most significantly associated with 
the established RBM20 consensus motif (UCUU) (Fig. 3B, C). In contrast, eCLIP of R636S HMZ iPSC-CMs 
identified 18,310 peaks in 2,794 genes. Most notably, more than 70% of RBM20 bound sequences within R636S 
HMZ iPSC-CMs were within the 3′ UTR of transcripts (Fig. 3B, Extended Data Table 3) and overlapped WT 
peaks in only 29 genes (e.g., CACNA1C, TTN, GNAI3, QKI). While the canonical RBM20 binding site remained 
the most enriched RNA recognition element (RRE) for R636S, secondary enrichments were found for PTBP1 
and FUS binding sites, RNA-binding proteins (RBPs) that are known to bind to the 3′ UTRs of transcripts in stress 
granules (Fig. 3C).  
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Given its cytoplasmic localization and previous indications that the R636S mutant interacts with stress granules 
(Schneider et al., 2020), we hypothesized that RBM20 R6363S might act as an RNA stabilization factor. To test 
this hypothesis, we compared the transcript localization distribution of RBM20 R636S to all other RBP eCLIP 
profiles from ENCODE (ENCODE Project Consortium, 2012). Indeed, the R636S eCLIP was most similar to the 
binding pattern of well-established processing-body (P-body)/stress-granule associated RBPs including PUM2, 
DDX6 and TIA1, all of which have eCLIP peaks enriched for the RBM20 binding site (Fig. 3D, Extended Data 
Fig. 2B). Direct comparison of R636S eCLIP peaks with all ENCODE eCLIP profiles resulted in a similar 
distribution of overlapping RBPs, including IGF2BP1 and TIAL1 (Fig. 3E). Interestingly, mutant RBM20 eCLIP 
binding sites also overlapped with those of a mutant form of FUS associated with ALS (P525L) (Fig. 3E) (De 
Santis et al., 2019). While mutant RBM20 eCLIP peaks were enriched in RNA-stabilization and cardiac 
contractile genes (Extended Data Fig. 2C, D), common peaks from both FUS-P525L and RBM20-R636S were 
also enriched in 3′ UTR AU-rich binding (e.g., ELAV1, ME3D, CPE3), ALS (e.g., SETX, DCTN3, TRAK2), PML 
body, cardiac contraction, and cell junction genes (Fig. 3F, Extended Data Table 4, 5). To assess the potential 
functional significance of these RBM20-R636S binding events, we performed deep RNA-Seq on WT (n = 8), 
R636S HTZ (n = 6), R636S HMZ (n = 3) and KO (n = 4) day 26 iPSC-CMs purified by sodium lactate treatment. 
Notably, R636S eCLIP peaks were relatively frequent (17%) among genes that were down-regulated in R636S 
versus RBM20 KO iPSC-CMs (Fig. 3G and Extended Data Table 6). Looking more broadly at global patterns 
of gene regulation identified striking differences between WT and KO or R636S iPSC-CMs, but only a few genes 
were consistently regulated in KO and R636S versus WT or between R636S HTZ and HMZ iPSC-CMs (Fig. 3H, 
Extended Data Fig. 2E and Extended Data Table 7). Among genes with the dominant pattern of up-regulation 
in the KO and coincident down-regulation in R636S iPSC-CMs, genes with R636S eCLIP peaks were abundant, 
including those for RBPs (DDX6 and the IGF2BP1 binding partner G3BP1) (Fig. 3H). Taken together, these data 
indicate that R636S RBM20 shares common binding sites with stress granule/P-body RBPs and with ALS mutant 
FUS, many of which are down-regulated only with R636S. 
Alternative splicing differences in R636S and RBM20 KO CMs impact distinct physiological pathways 
Prior RBM20 KO studies in mice and rats, and patient RNA-Seq studies have identified a large number of 
RBM20-dependent splicing events implicated in DCM pathophysiology. To investigate the role of RBM20-
mediated splicing in cardiac development, we first performed deep RNA-Seq of wild-type iPSCs at various 
stages of differentiation (Extended Data Fig. 3, 4 and Extended Data Table 8-13). To detect changes in 
global splice patterns, we used a combination of analysis software (AltAnalyze and MultiPath-PSI; see 
Methods for details), allowing for an unbiased and quantitative comparison of known and novel splicing events 
between time points (Emig et al., 2010; Salomonis et al., 2010; Itskovich et al., 2020). In normal iPSC-CM 
differentiation, we observed an RBM20 splicing program induced in lock-step with an increase in RBM20 gene 
expression (Extended Data Fig. 4J). These include well-established RBM20 target exons in TTN and 
CAMK2D. Notably, all novel cardiac differentiation splicing events tested (n=17) were readily verified by RT-
PCR or targeted sequencing, indicating that our splicing analysis predictions are highly accurate (Extended 
Data Fig. 4H, I and Extended Data Table 12). Having confirmed the sensitivity of these algorithms and the 
emergence of an endogenous RBM20 splicing program during differentiation, we performed a global splicing 
analysis in gene-edited RBM20 iPSC-CMs. In R636S HTZ, we identified 116 splicing events that differed from 
those in WT iPSC-CMs using a conservative LIMMA-based analysis (Fig. 4A; Extended Data Table 14; 
Methods). These include several prior validated targets affected in DCM patients with the RBM20 S635A 
mutation, such as TTN, CAMK2D, OBSCN, RYR2, IMMT, and TNNT2) (Fig. 4B-D, and Extended Data Fig. 
5B) (Guo et al., 2012). Several of these splicing events showed a clear dosage-dependent splicing pattern and 
overlap with RBM20 WT eCLIP peaks, suggesting that they are direct targets (e.g., TTN, CDC14B, GSE1, 
RYR2, SPATS2), while others had the same extent of splicing-deregulation with one or two alleles of R636S 
(e.g., NEO1, IMMT, DMD) (Fig. 4B, D-E). Approximately 80% of the RBM20 R636 HTZ alternative splicing 
events found were associated with cassette-exon splicing, in particular exon inclusion, consistent with prior 
reports (Fig. 4A) (Maatz et al., 2014). Notably, we found that >50% of these R636S-dependent splicing events 
were secondarily observed in independent RBM20 DCM mutant edited iPSC lines from our laboratory and 
others (Extended Data Fig. 5A; Extended Data Table 15-18). To assess the potential developmental 
regulation of these splicing events, we examined them in our WT iPSC-CM differentiation time-course. This 
analysis finds that R636S results in a developmental reversion of splicing for several well-described and novel 
RBM20 target exons (e.g., CAMK2D, TTN, GSE1) (Extended Data Fig. 4E, F; Extended Data Fig. 5A), along 
with others verified by RT-PCR (Extended Data Fig. 5I). 
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To identify predominant patterns of splicing in R636S mutation and RBM20 KO cells, we applied the same 
supervised-pattern analysis we applied to the gene expression data (Fig. 4C; Extended Data Table 19; 
Methods). This analysis revealed stark differences in the patterns of splicing compared to gene expression. 
Specifically, we observed splicing differences largely specific to the HTZ or HMZ R636S mutants, in addition to 
splicing differences uniquely shared by R636S HTZ and HMZ, those specific to RBM20 KO or shared among all 
R636S and RBM20 KO samples. The R636S/KO shared events frequently overlapped with WT eCLIP peaks 
and included the majority of prior validated RBM20 targets from human heart and rat RBM20 truncation mutant 
studies (Guo et al., 2012; Maatz et al., 2014). As these splicing events co-occurred in KO cells, they likely are 
the result of nuclear depletion of RBM20. Intriguingly, splicing-events specific to the R636S mutants or KO 
represented the dominant pattern of splicing and suggest that R636S does not simply phenocopy loss of RBM20 
expression. Such R636S and KO-specific events included splicing regulators themselves (e.g., LUC7L3) as well 
as putative heart contractile disease mediators (SLC44A2, SLCA81, SVIL) (Fig. 4F-I; Extended Data Fig. 5). 
To determine whether such spliced exons are also present in an in vivo model of RBM20 DCM, we re-analyzed 
recent RNA-Seq from R636S gene-edited neonatal pigs, with HTZ and HMZ alleles (Schneider et al., 2020). 
This analysis verified splicing events within all observed splicing patterns that were conserved to pig at the level 
of exon-exon junctions (Fig. 4C; Extended Data Fig. 6; Extended Data Table 20). R636S-unique splicing 
patterns were further evidenced by R636S intronic eCLIP binding sites as well independent iPSC-CM RNA-Seq, 
with RBM20 missense and non-sense mutations (Fig. 4C). Gene-set enrichment analysis of RBM20 splicing 
events that fell into the three major patterns (commonly regulated, specific to KO, specific to R636S), highlighted 
distinct cardiac contractility, physiology and signaling pathways that represent potential areas for targeted 
exploration in the future, including ion channel-specific splicing differences found only in R636S (e.g., TRPC3, 
CACNA1G, CACNA1D, CACNB3, KCNH2, KCNC4) (Fig. 4J and Extended Data Table 21). In summary, we 
find that R646S and RBM20 KO result in largely distinct changes in splicing and that such human iPSC-CM 
events are conserved in a R636S pig model of DCM. 
Mutant and KO RBM20 alter circular RNA production and alternative polyadenylation 
In addition to alternative splicing, recent studies suggest that circular RNAs, in particular those in TTN, may also 
contribute to RBM20-DCM pathology (Aufiero et al., 2018; Tijsen et al., 2021). Using an RNA-Seq protocol 
sensitive to circRNAs we found that R636S mutants produce a far greater number of circRNAs than RBM20 KO 
iPSC-CMs (Extended Data Table 22). Consistent with prior studies, the most frequently detected circRNAs 
were found in TTN, with relatively few differential circRNA exons/introns containing RBM20 eCLIP binding sites 
or overlapping with alternatively spliced-exons (Extended Data Fig. 7A, B). 
While not previously implicated in RBM20 biology, we further asked whether alternative polyadenylation (APA) 
occurred in the setting of mutant or KO KBM20 from our RNA-Seq. Analysis of differential APA events using the 
QAPA algorithm highlighted ~1,200 events that were significantly associated with the dominant patterns of 
RBM20 mutant and KO regulation (Extended Data Fig. 7C and Extended Data Table 23). KO-induced APA 
events were enriched in mutant RBM20 eCLIP targets, which were predicted to mediate heart morphogenesis, 
the Golgi-network, cell-cycle, transcriptional regulation, cell-junctions, WNT and BMP signaling, as well as 3’UTR 
AU-rich binding (Extended Data Fig. 7D, E and Extended Data Table 24). These data suggest that APA may 
represent a novel form of RBM20-dependent gene regulation that alters the ability of RBM20 to associate with 
3’UTR targets. 
R636S mutant RBM20 with co-localizes with cytoplasmic processing bodies 
Based on our eCLIP comparative analyses, we predicted that mutant RBM20 may specifically localize within 
processing bodies (P-bodies), cytoplasmic ribonucleoprotein granules that exist in a liquid phase and may act to 
repress mRNA translation (Luo et al., 2018). Importantly, P-bodies are distinct from stress granules, which are 
transient protein-RNA ensembles that assemble in response to acute stress, and disassemble when the stimulus 
is removed (Protter and Parker, 2016; Wheeler et al., 2016), although current models conflict on the question of 
whether P-bodies and stress granules interact during acute stress (Hubstenberger et al., 2017; Chantarachot 
and Bailey-Serres, 2018; Luo et al., 2018). The protein DDX6 was highlighted as one of the most likely RBM20 
interacting P-body candidates from our analyses, as it shares predicted binding sites and binding profiles with 
RBM20 R636S. High-magnification imaging revealed that a subset of cytoplasmic RBM20 in mutant iPSC-CMs 
co-localized with P-bodies as visualized with DDX6 (Figs. 5A-C). RBM20 co-localized with DDX6 to a greater 
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degree in R636S HMZ than HTZ iPSC-CMs, and essentially no co-localization was observed in WT cells. Another 
P-body factor highlighted from our eCLIP analyses was IGF2BP1, which associates with the stress granule-
promoting factor G3BP1. No stress granules were present in iPSC-CMs under basal culture conditions, in which 
G3BP1 displayed a diffuse cytoplasmic localization (Fig. 5D). However, following treatment with 1 mM sodium 
arsenate for 1 hour, iPSC-CMs rapidly assembled conspicuous stress granules (Fig. 5D, E). Under these acute 
stress conditions, mutant RBM20 co-localized with stress granules, but with WT protein did not (Fig. 5E). Hence, 
these data strongly support a model by which mutant RBM20 impacts alternative splicing through broad non-
nuclear 3′ UTR binding and association with P-bodies, a mechanism that is reminiscent of neurological diseases 
associated with RNA-binding protein cytoplasmic aggregation (Fig. 6). 
 
DISCUSSION 
Our understanding of the molecular and physiological effects of RBM20 mutations has remained elusive largely 
due to a lack of appropriate models that are not confounded by heart disease or patient genetics. Here, we 
applied precision targeting of an RBM20 patient genetic mutation in human iPSC-CMs as a model system to 
evaluate the impact of specific patient alleles and RBM20 KO. This controlled system allowed us to delineate 
the impact of RNA biogenesis on excitation-contraction coupling attributable to a single-variant substitution. We 
demonstrated distinct phenotypes via MEA between R636S mutant and RBM20 KO iPSC-CMs. Importantly, 
although previously reported (mouse, rat and pig) HTZ animal models of RBM20 DCM did not exhibit contractile 
defects, our RBM20 R636S 3D-EHTs (HTZ and HMZ) demonstrate a significant contractile phenotype compared 
to WT. Thus, this work establishes human iPSC-CM 3D-EHTs as a powerful and physiologically relevant model 
to study RBM20 DCM and therapeutic development.  
 
Immunofluorescence experiments confirmed that the RBM20 R636S mutant protein mis-localizes to the 
cytoplasm. However, super-resolution microscopy revealed that a subset of mutant RBM20, even in R636S HMZ 
iPSC-CMs, maintains some capability to localize to the nucleus. Intriguingly, immunofluorescence showed that 
mutant RBM20 in mutant, but not WT iPSC-CMs co-localizes with P-bodies, cytoplasmic RNP granules present 
under basal conditions, that are sites of mRNA storage and turnover. During the preparation of this manuscript, 
the Schneider lab reported that mutant RBM20 co-localizes with stress granules in cells treated with sodium 
arsenate (Schneider et al., 2020). Stress granules are distinct from P-bodies, and are assembled in response to 
acute stress which inhibits translation (e.g., sodium arsenate, sorbitol, UV). Our data demonstrate that under 
basal culture conditions, WT and RBM20 mutant iPSC-CMs do not contain stress granules, but only assemble 
canonical stress granules in response to acute stress. Under these acute stress conditions, RBM20 in mutant, 
but not WT iPSC-CMs, does co-localize with stress granules. Schneider′s group also reported liquid-like behavior 
of mutant RBM20 (e.g., RBM20 potentially undergoes a “liquid-liquid phase separation”). As P-bodies have been 
demonstrated to represent a bona-fide liquid-liquid phase separated compartment (Hondele et al., 2019; You et 
al., 2020), association with P-bodies may drive this liquid-like behavior of mutant RBM20. Further investigation 
is warranted to better understand the functional consequences of the liquid-like behavior of cytoplasmic RBM20 
on cellular physiology. 
 
To understand the molecular consequences of mutant RBM20 in the nucleus and cytoplasm, we performed 
unbiased eCLIP profiling of wild-type and R636S iPSC-CMs. The results reveal a change in spliceosome-
mediated target interactions in the setting of mutant RBM20 due to nuclear depletion of RBM20 and an altered 
bias towards consensus binding sites within the 3′ UTR of distinct transcripts. These 3′ UTR targets provide 
insight into the function of mutant RBM20, as many are shared with other RNA stabilization factors involved in 
pathogenic granule formation, including mutant FUS (Sabatelli et al., 2013). These data provide strong evidence 
that mutant RBM20 mimics previously described factors that mediate P-body and stress granule formation, and 
it may recruit additional factors to these bodies.  
 
Importantly, our alternative splicing predictions further suggest a more complex model of the role of mutant 
RBM20 in cardiomyopathy pathogenesis. Specifically, although R636S RBM20 molecules are largely absent 
from the nucleus, we observed highly contrasting splicing signatures between KO and HMZ mutant cells. The 
importance of these mutation-specific splicing events, the targets of which include genes involved in cardiac 
development, and structural and contractile regulators, are supported by the finding of orthologous R636S-
induced events in neonatal pigs and/or that exhibit overlapping mutant-specific eCLIP peaks. Additional 
observations from circular RNA analyses indicate that mutant RBM20 affects circular RNA production, supporting 
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prior observations that such molecular events preferentially impact constitutive exons, while alternative 
polyadenylation analyses suggest a broader role RBM20 in post-transcriptional gene regulation (Aufiero et al., 
2018). While the precise cause of and functional relevance of splicing differences in mutant and wild-type remain 
to be determined, these data suggest a more complex model in which loss of canonical RBM20 splicing leads to 
altered functional products involved in cardiac contractile regulation, potentially augmented by pathogenic 
circular RNAs, the emergence of new splice-forms in cardiac developmental and signaling genes, global changes 
in polyadenylation, and the degenerative accumulation of cytoplasmic granules impacting cardiomyocyte 
homeostasis.  
 
It is intriguing to note the parallels between our observations with RBM20 and recent findings in neuro-
degeneration. Indeed, recent work has hypothesized cytoplasmic RBM20 may be similar to the cytoplasmic RNP 
granules associated with neurodegeneration (Schneider et al., 2020), such as TAU for Alzheimer′ s disease, 
Huntingtin for Huntington′ s disease, and FUS for amyotrophic lateral sclerosis (ALS) (Conlon and Manley, 2017; 
Maziuk et al., 2017). We add to this initial hypothesis by demonstrating that under basal conditions, mutant 
RBM20 binds to 3′ UTR regions of mRNA and co-localizes with P-bodies. Our study indicates that protein 
granules are a critical determinant factor for not only neurodegenerative disease but potentially more diverse 
diseases including cardiomyopathy. This is an intriguing notion, but further mechanistic studies are required to 
determine the functional consequences of the cytoplasmic localization and association of mutant RBM20 with P-
bodies.  
 
These analyses illustrate important differences in the splicing targets of mutant RBM20, with data from iPSC-
CMs likely indicating that defects during early cardiogenesis could lead to remodeling of the fetal heart. While 
such molecular changes in iPSC-CMs may not recapitulate the gross-cardiac remodeling defects that impact 
heart function in patients with RBM20 mutations, we hypothesize that such splicing differences may predispose 
to later cardiovascular events. Importantly, these human cellular models provide the cardiovascular research 
community with powerful tools to aid in the development of new therapeutic targets for heart disease. 
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MATERIALS AND METHODS 
iPSC Culture 
The UCSF Committee on human research #10-02521 approved the study protocol for iPSCs. The human iPSC 
lines used in this study were generated from a healthy male patient, WTC11 (Kreitzer et al., 2013; Miyaoka et 
al., 2014) using the episomal reprogramming method (Okita et al., 2011). Informed consent was obtained for this 
procedure. iPSCs were maintained on Matrigel (BD Biosciences) in Essential 8 medium (Life Technologies), 
which was exchanged every other day. To sparsely populated wells (i.e., passaged wells), we added 10 μM Y-
27632, a Rho-associated kinase (ROCK) inhibitor (Millipore), to promote cell survival. 
  
RBM20 Mutant iPSC Line Generation 
We applied our ddPCR and sib-selection based strategy to isolate genome-edited iPSC lines, as previously 
described (Miyaoka et al., 2016, 2014). We used TALENs targeting exon 9 of RBM20 (Addgene #108342 and 
#108343) to generate the RBM20 R636S Het iPSC line, which was then retargeted by CRISPR/Cas9 nickase 
(pX335; Addgene #42335) to convert the WT allele to the R636S with a S635S silent mutation allele. We used 
the Human Stem Cell Nucleofector Kit-1 and a Nucleofector 2b Device (Lonza) to transfect the plasmids and 
oligonucleotide donor DNA. For each transfection, 2 million cells were transduced with 3 μg of each TALEN 
vector or pX335 and 6 μg of an oligonucleotide donor DNA using program A-23. The transfected cells were 
plated into a Matrigel-coated 96-well plate using a multichannel micropipetter. The detailed information of the 
TALENs, gRNAs, and oligonucleotide donor DNA are summarized in Supplemental Methods. Karyotyping was 
performed by Cell Line Genetics. 
 
The composition of the premixtures of allele-specific TaqMan probes and primers for ddPCR analysis was 5 μM 
of an allele-specific FAM or VIC TaqMan MGB probe (Thermo Fisher Scientific), 18 μM of a forward primer and 
18 μM of a reverse primer (Integrated DNA Technology) in water. To detect point mutagenesis, we mixed the 
following reagents in 0.2 ml PCR 8-tube strips: 4 μl water, 12.5 μl 2× ddPCR Supermix for probes (Bio-Rad), 
1.25 μl R636S+SM FAM probe and primer premixture, 0.625 μl WT VIC probe and primer premixture, 0.625 μl 
R636S FAM probe and primer premixture, and 5 μl (50–150 ng) genomic DNA solution (25 μl total volume). The 
conditions for droplet generation, thermal cycling, and data analysis for RBM20 R636S mutagenesis with the 
ddPCR system were described before (Miyaoka et al., 2014, 2016). As the R636S+SM FAM probe had a higher 
concentration than the WT FAM probe, the signal of the R636S+SM allele was distinguishable from that of the 
WT allele (Extended Data Fig. 1). Cell populations with a higher frequency of the R636S+SM allele and a lower 
frequency of the WT allele were enriched by sib-selection until the RBM20 R636S HMZ iPSC clone was isolated. 
  
iPSC-CM differentiation 
For genomic analyses (Figs. 1, 3, and 4) The iPSC lines were differentiated into iPSC-CMs using the method 
that controls WNT signaling by small molecules (the GiWi protocol) (Lian et al., 2013). Briefly, iPSCs were 
seeded at 1.25-2.5x104 cells/cm2 onto 12-well plates coated with 80 μg/μl growth factor-reduced Matrigel (BD 
Biosciences) in mTeSR1 supplemented with 10 μM Y-27632 (Millipore) for 24 h (day 3). mTeSR1 medium was 
changed daily for the next 2 days. On day 0, iPSCs were treated with 12 μM CHIR99021 (CHIR) (Tocris) in RPMI 
supplemented with B-27 (RPMI/B27) without insulin (Life Technologies) for exactly 24 h. On day 1, the culture 
medium was replaced with fresh RPMI/B27 without insulin and maintained for 48 h. On day 3, cells were treated 
with 5 μM IWP2 (Tocris) in RPMI/B27 without insulin and maintained for 48 h. On day 5, fresh RPMI/B27 without 
insulin was added to the cells, and on day 7, the medium was switched to RPMI/B27 with insulin. Afterward, 
fresh RPMI/B27 with insulin was added to the cells every 3 days. We used a metabolic selection protocol with 
glucose-free DMEM containing lactate to purify iPSC-CMs. Cells were replated on day 15-18 of differentiation, 
and then on day 20-22 media were replaced with DMEM (without glucose, with sodium pyruvate, Thermo Fisher 
Scientific) supplemented with Glutamax, non-essential amino acids, and buffered lactate (4 mM). Stock-buffered 
lactate solution was prepared by dissolving sodium L-lactate powder (Sigma-Aldrich) at 1 M concentration in 1 
M HEPES solution. Lactate media were exchanged 2-3 times, with a total exposure of 48 hours for each 
treatment. After the final lactate treatment, media were changed to RPMI/B27 with insulin. The purified WT or 
RBM20 mutant iPSC-CMs at day 26 were harvested for RNA-Seq or cryopreserved for further analyses. 
 
For electrophysiological, contractile, and immunofluorescence analyses, iPSCs were maintained on Matrigel 
(Fisher Scientific) and in mTesr Plus (StemCell Technologies) culture media, which was exchanged every 
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other day. For iPSC-CM differentiation, iPSCs were plated in 12 well plates (Fisher Scientific) coated with 
Matrigel in mTesr Plus supplemented with 10 μM Y-27632 (StemCell Technologies) for 24 hours. On day -1, 
iPSCs were treated with 1 μM CHIR-99021 (Cayman Chemical) to prime cells for differentiation. On day 0, 
iPSCs were treated with RPMI-1640 with glutamine supplemented with 500 μg/ml BSA, 213 μg/ml ascorbic 
acid (RBA media; Millipore Sigma) and 5 μM CHIR-99021 for 48 hours. On day 2, cells were treated with RBA 
media supplemented with 2 μM WNT-C59 (Selleck Chemicals). On day 4, cells were treated with RBA. 
Starting on day 6, iPSC-CMs were maintained in RPMI + B27 (ThermoFisher) with media exchanges every 2 
days. On day 13, iPSC-CMs were pre-conditioned with a 45-minute heat shock at 42°C (pre-warmed 42°C 
media was exchanged prior to incubation) to enhance survival of cryopreservation and thawing process. On 
day 14, iPSC-CMs were frozen in batches (>5 million cells) in CryoStor media (1 million cells/100 μLs 
CryoStor; Millipore Sigma) and placed in liquid nitrogen for disease modelling experiments. To passage cells 
for freezing, cells were washed with 1x DPBS (no magnesium, no calcium; ThermoFisher), and treated with 
10x TrypLE (ThermoFisher) for 10 – 20 minutes at 37 °C. Cells were dissociated with mild trituration and 
passed through a 100 μM strainer (Fisher Scientific) to remove any large clumps (which negatively impact 
survival in our hands). 
 
Frozen iPSC-CM stocks were thawed onto 6-well plates coated with Matrigel at 2.5 – 3 million cells/well in 
RPMI- B27 supplemented with 10 μM Y-27632 and 10% FBS. 24 hours post thaw, media was exchanged for 
RPMI-B27. After 48 hrs recovery, iPSC-CMs were purified in no glucose DMEM + 4 mM sodium lactate to 
select for iPSC-CMs for a total of 4 days (media was exchanged at day 2 of treatment). After 4 days, media 
was exchanged with RPMI-B27 and iPSC-CMs were allowed to recover for one day before re-platting (as 
above) for subsequent studies at day 21 post-differentiation. 
 
Flow-cytometry 
Day 15 cells were dissociated to single cells using 0.2 mL of 0.25% Trypsin (UCSF Cell Culture Facility) per well 
of a 24-well plate with incubation at 37°C. Cells were resuspended in 0.8 mL/well EB medium (Knockout DMEM 
supplemented with 20% FBS (HyClone), Glutamax (Gibco), Non-essential Amino Acids (UCSF Cell Culture 
Facility), and 0.1 mM beta-Mercaptoethanol (Sigma)). 200 μl (about 200,000) cells were pelleted and fixed in 4% 
paraformaldehyde at room temperature for 15 minutes. Cells were permeabilized in FACS Buffer (DPBS without 
calcium and magnesium, 4% FBS, and 2 mM EDTA (Gibco)) with 0.5% (w/v) saponin (Sigma). Cells were stained 
with 100 μl of 0.002 μg/μl (1:100) Mouse anti-human cardiac Troponin T (cTnT) primary antibody (Thermo, MS-
295-P) in FACS Buffer with saponin at room temperature for 30 minutes and washed. Cells were then stained 
with 100 μl of 0.01 μg/μl (1:200) Alexa Fluor 488 goat anti-mouse IgG secondary antibody (Invitrogen, A-11029) 
in FACS Buffer with saponin at room temperature for 30 minutes and washed. Finally, cells were stained with 
100 μl of 0.01 μg/μl (1:1000) Hoechst 33342 (Molecular Probes) in FACS buffer at room temperature for 5 
minutes and passed through a 0.4 μm filter (Millipore) to remove cell clumps. Data were collected using the 
MACSQuant VYB flow cytometer (Miltenyi Biotec) and analyzed using FlowJo. 
 
RNA-sequencing 
Total RNA was purified from iPSC-CMs by using TRIzol and PureLink RNA Mini Kit (Thermo Fisher Scientific) 
according to the manufacturer’s instructions. The RNA-Seq libraries were prepared from the purified RNA by 
using TruSeq RNA Library Prep Kit v2 (Illumina) for gene and splicing analyses or the RiboMinus for 
Ribosomal RNA Depletion protocol (Thermofisher) for circular RNA splicing analyses. Paired-end RNA-Seq 
was performed with HiSeq (Illumina). An average of ~90 million reads were obtained from this iPSC RNA-Seq 
data. RNA-Seq for WTB iPS differentiation was performed as biological replicates (n=2), whereas the number 
of samples processed for WTC iPSC-CMs verified from 3-7 replicate samples per genotype. 
  
eCLIP 
RBM20 WT and RM20-R636S direct transcript binding sites were determined using the same RBM20 polyclonal 
antibody (ThermoFisher, Cat#PA5-58068) on WT or R636S HMZ WTC iPS CMs using the eCLIP protocol as 
previously described  (Van Nostrand et al., 2016). RNA-libraries were sequenced at a depth of 30-40 million 
reads for each replicate eCLIP sample, on an Illumina HiSeq 2500 (single-end reads). Reproducible RBM20 
peaks (hg19) obtained from replicate WT and R636S HMZ iPSC-CMs compared to size-matched input controls, 
were used for all down-stream analyses. eCLIP peaks (hg19) from all prior generated ENCODE RNA-binding 
proteins (K562 and HEPG2 cell lines) were obtained from https://www.encodeproject.org/eclip/. Additionally, 
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peaks associated with the ALS mutation in the gene FUS (P525L) were aggregated within a 200nt window using 
the software bedtools (merge function), only found in the mutant and not the FLAG tagged eCLIP, following 
liftover from hg38 to hg19 (GSE118347). To identify RNA recognition elements (RRE) associated with known 
RNA-Binding Proteins, we analyzed reproducible RBM20 peaks using the software HOMER using de novo motif 
discovery with the CisBP-RNA database (Ray et al., 2013; Heinz et al., 2010).  All eCLIP peaks were annotated 
according to the gene intervals they correspond to (e.g., exon, introns, 3′ ends, 3′ UTR, distal or proximal regions) 
using predictions produced from clipper (https://github.com/YeoLab/clipper/). eCLIP peaks overlapping between 
different RBPs were identified using the bedtools intersect -wb option. 
RNA-Seq Analysis 
RNA-Seq FASTQ files were aligned to the human hg19 reference genome and transcriptome using the software 
STAR. STAR produced BAM files were further processed in AltAnalyze (version 2.1.4) to obtain gene expression 
(RPKM values) and splicing estimates (PSI). Gene expression differences across the 11 CM differentiation time-
points were calculated as pairwise comparisons to day 0 and to the prior time-point, for gene-set enrichment 
analysis and to restrict genes for pattern-based analyses (MarkerFinder algorithm in AltAnalyze) using an 
empirical Bayes moderated t-test p<0.05 (FDR corrected) and at least a 2-fold difference with a minimum RPKM 
value of 1 in either of the two groups compared. To accurately detect diverse alternative splicing events in iPSC-
CM RNA-Seq, we used a recently described Percent Spliced-In splicing approach, called MultiPath-PSI, capable 
of accurate detection of known and novel exonic and intronic splicing events, as well as alternative promoter-
associated exons (Itskovich et al., 2020; Muench et al., 2018; Rindler et al., 2017).  Alternative polyadenylation 
was predicted and quantified using the software QAPA with default options to produce alternative isoform ratios 
for each 3′ UTR isoform, normalized to the total 3′ UTR form for each gene (Ha et al., 2018).  
Application of MultiPath-PSI to all evaluated mutant and matched human WT samples identified 44,911 detected 
splicing events, corresponding to 16,207 unique splicing events. Prior differential splicing analysis, empirically 
observed gene expression associated differentiation effects were evaluated using unsupervised subtype 
detection analysis with the software Iterative Clustering and Guide-gene Selection (ICGS) (Olsson et al., 2016). 
Since the identified transcriptomic differences among independent iPSC-CM differentiations couldn′t 
be associated with iPSC genetic background, we surmise they are likely due to differentiation associated 
cardiac maturity. To account for these empirically observed effects, we applied a mixed effects linear model to 
account for these differentiation effects. For this model, each pair of differentiation-associated transcriptional 
effects was evaluated using LIMMA using the lmfit function to account for these effects in addition to cell line 
genetics in the linear model. See https://www.synapse.org/#!Synapse:syn25835429 for details.
For the differential splicing analysis, events were filtered for event detection in 75% of the samples in each 
biological group along with a change in PSI between the two groups greater than 10% (dPSI > 0.1). The 
supervised splicing pattern analysis was performed on unique (splicing-junction clusterID) identified differentially 
spliced events using the R packages LIMMA to obtain a two-tailed empirical Bayes moderated t-test p-value for 
the following models: 1) R636S HTZ-specific splicing, 2) R636S HMZ-specific splicing, 3) equivalent differential 
splicing in R636S HTZ and HMZ, and 4) additive induction in the HTZ to HMZ R636S. To identify splicing events 
associated with the predominant genetically-defined patterns, we applied the MarkerFinder algorithm, iterated 
over multiple sample groupings (all primary groups and aggregated groups of mutations - e.g., R636S-HTZ plus 
R636S-HMZ), for empirical Bayes moderated t-test significant events (p<0.05). This algorithm was also used for 
gene expression and alternative polyadenylation analyses, to define the major RBM20-dependent patterns 
(iterativeMarkerFinder function from https://git.io/Jt9je). Alternative splicing events from independently edited 
WTB iPSC-CMs with R636S HTZ and controls were quantified as above by TruSeq RNA-Seq, followed by 
AltAnalyze and MultiPath-PSI (dSPI>0.1). Similarly, RNA-Seq FASTQ files from a prior study were 
downloaded from PRJNA579336, to identify differential splicing results associated with missense or nonsense 
HMZ RBM20 mutations and controls, using AltAnalyze and MultiPath-PSI (dSPI>0.1 and empirical Bayes 
moderated t-test p<0.05) (Briganti et al., 2020). Gene-set enrichment analyses were performed with the 
software GO-Elite in AltAnalyze (Zambon et al., 2012). 
To identify, quantify and annotate circular RNAs from back-splice junctions we first aligned the RNA-Seq results 
using TopHat2 on the RiboMinus depleted paired-end RNA-Seq FASTQ files, via the CIRCexplorer2 pipeline, 
on each individual sample (default options). This workflow identified far greater putative circRNAs than using the 
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same pipeline with STAR 2.4.0. For differential circRNA analysis we ran RUVSEQ from the CSBB pipeline 
(https://github.com/csbbcompbio/CSBB-v3.0) on the back-splice junction counts for each sample for all relevant 
comparison groups. This workflow applies the software EdgeR to perform a differential expression analysis using 
a generalized linear model approach using the upper quartile normalization. All together, we identified circRNAs 
for 448 genes, with evidence of at least two reads per circRNA. circRNAs with a non-adjusted EdgeR p<0.1 were 
considered differentially expressed. 
 
To determine genomic coordinate overlaps between: a) eCLIP peaks and alternative splicing events, b) eCLIP 
peaks and alternatively expressed circRNAs or c) alternative splicing events and alternatively expressed 
circRNAs, we created a multi-use script that leverages transcriptomic feature genomics coordinates and their 
overlap in AltAnalyze (https://git.io/JtHfa). For alternative splicing the MultiPath-PSI reported alternative exon 
and flanking intron genomic positions were directly intersected against eCLIP peaks. Similarly, the regulated 
exon(s) and flanking introns were considered for overlap for circRNAs.  
 
Quantitative PCR Analysis 
Gene expression analysis was performed on the total RNA isolated during iPS cell differentiation into CMs. cDNA 
was generated from 1 μg of TurboDNAse-treated (Ambion) total RNA with the SuperScript III First Strand 
Synthesis kit and random hexamers (Invitrogen) as described by the manufacturer. Expression was assessed 
using TaqMan probesets run on the 7900HT real-time thermocycler (Applied Biosystems). Samples were 
assayed in technical triplicate, normalized to GAPDH or UBC, and relative expression was calculated with the 
day of highest expression set to 100%. 
 
Automated Primer Design and RT-PCR Analysis of ASEs 
To validate alternatively spliced exons, the primer design program Primer3 (Rozen and Skaletsky, 2000) was 
integrated with AltAnalyze (identifyPCRregions function in the EnsemblImport module). As sequence input the 
alternative spliced exon, junctions and associated isoforms were used to identify the target region in the inclusion 
isoform (included/excluded exon), and suitable upstream and downstream exon sequences shared by the two 
isoforms. RT-PCR was conducted using these primers (Extended Data Table 12), random hexamer generated 
cDNA (described above), and Platinum Taq DNA Polymerase High Fidelity (Life Technologies) as described by 
the manufacturer. 
 
Engineered Heart Tissue Casting 
3-dimensional engineered heart tissues (3D-EHTs) were cast and characterized as previously described 
(Leonard et al., 2018). Polydimethylsiloxane (PDMS) posts were fabricated by pouring uncured PDMS (Sylgard 
184 mixed at a 1:10 curing agent to base ratio) into a custom acrylic mold (Limited Productions Inc., Bellevue, 
WA; design available upon request). Glass capillary tubes (1.1 mm in diameter; Drummond) were cut to length 
and inserted into the holes on one side of the mold before curing to render one post in each pair rigid. Post 
racks were baked overnight at 65°C before being peeled from the molds. Racks consisted of six pairs of posts 
that were evenly spaced to fit along one row of a standard 24-well plate. Fabricated posts were 12.5 mm long 
and 1.5 mm in diameter with a cap structure (2.0 mm in diameter for the topmost 0.5 mm) to aid in the 
attachment of 3D-EHTs. The center-to-center post spacing (corresponding to pre-compacted 3D-EHT length) 
was 8 mm. Prior to casting 3D-EHTs, all 3D-printed parts and PDMS posts were sterilized in a UVO Cleaner 
(342; Jetlight) for 7 min, submerged in 70% ethanol, and rinsed with sterile deionized water. Rectangular 2% 
wt/vol agarose/PBS casting troughs (12 mm in length, 4 mm in width, and ∼4 mm in depth) were generated in 
the bottom of 24-well plates by using custom 3D-printed spacers (12 mm × 4 mm in cross-section and 13 mm 
long) as negative molds. PDMS post racks were positioned upside down with one rigid-flexible post pair 
centered in each trough (leaving a 0.5-mm gap between the tip of the post and the bottom of the casting 
trough). Each tissue consisted of a 97-µl fibrinogen-media solution (89 µl of RPMI-B27, 5.5 µl of DMEM/F12, 
and 2.5 µl of 200 mg/ml bovine fibrinogen; Sigma-Aldrich) containing 5 × 105 iPSC-CMs and 5 × 104 supporting 
HS27a human bone marrow stromal cells (ATCC), which was chilled and mixed with 3 µl of cold thrombin (at 
100 U/ml; Sigma-Aldrich) just before pipetting into the agarose casting troughs. The 3D-EHT mixtures were 
incubated for 90 min at 37°C, at which point the fibrin gels were sufficiently polymerized around the posts to be 
lubricated in media and transferred from the casting troughs into a 24-well plate with fresh 3D-EHT media 
(RPMI-B27 with penicillin/streptomycin, and 5 mg/ml aminocaproic acid; Sigma-Aldrich). 3D-EHTs were 
supplied with 2.5 ml/well of fresh 3D-EHT media three times per week. 
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In situ contractile measurements were performed at 3-weeks post casting of 3D-EHTs. To pace 3D-EHTs, post 
racks were transferred to a custom-built 24-well plate with carbon electrodes connected through an electrical 
stimulator (S88X; Astro Med Grass Stimulator) to provide biphasic field stimulation (5 V/cm for 20-ms 
durations) during imaging (Leonard et al., 2018). 3D-EHTs were equilibrated in Tyrode’s buffer (containing 1.8 
mM Ca2+) preheated to 37°C and paced at 2 Hz, which was greater than the average spontaneous twitch 
frequency of the tissues. Videos of at least 10 contractions were recorded inside a 37 °C heated chamber 
using a monochrome CMOS camera (ORCA-Flash4.0). The camera lens configuration allowed for a capture 
rate of 66 fps with 8.3 µm/pixel resolution and a FOV of 1,536 × 400 pixels, which was sufficient to capture 
images of the whole 3D-EHT from rigid to flexible post. A custom Matlab program was used to threshold the 
images and track the centroid of the flexible post relative to the centroid of the rigid post. The twitch force 
profile, Ftwitch(t) = kpost × Δpost(t), was calculated from the bending stiffness kpost and deflection of the flexible post 
Δpost at all time points (t), where kpost = 0.95 μN/µm was determined from beam bending theory using the 
dimensions of the posts and taking the Young’s modulus of PDMS to be 2.5 MPa (Sniadecki and Chen, 2007). 
The twitch force and twitch kinetics were calculated from the twitch force profiles using a custom Matlab 
program. For statistical significance testing, one-way ANOVA with a Dunnett’s correction for multiple 
comparisons was performed. 
Multi Electrode Array (MEA) 
iPSC-CMs were plated (as above) at 100,000 cells per well directly on the electrode array of a 24 well MEA 
plates (CytoView MEA 24, Axion Biosystems) pre-coated with matrigel. RPMI-B27 was exchanged every two 
days. MEA analysis occurred at day 35 post differentiation (2 weeks post plating on MEA plates). MEA data 
was acquired at 37°C and 5% CO2 and recordings were acquired for 5 min using the Maestro MEA system 
(Axion Biosystems) using standard recording settings for spontaneous cardiac field potentials. Automated data 
analysis was focused on the 30 most stable beats within the recording period. The beat detection threshold 
was dependent on the individual experiment, and the FPD was manually annotated to detect the T-wave. The 
FPD was corrected for the beat period according to the Fridericia’s formula: FPDc = FPD/(beat period)1/3  
(Millard et al., 2018; Asakura et al., 2015; Rast et al., 2016). Results for individual wells were calculated by 
averaging all of the electrodes. For each MEA experiment, 4 technical replicates per condition were averaged, 
and reported results represent the average of 3 distinct biological replicates. For statistical significance testing, 
one-way ANOVA with a Dunnett’s correction for multiple comparisons was performed. 
 
Fixation and immunohistochemistry 
For images in Figures 2 and 5, iPSC-CMs were fixed with 4% paraformaldehyde (PFA) in PBS at room 
temperature for 20 min and then extracted for 5 min with 0.3% Triton X-100 and 4% PFA in PBS as previously 
described (Burnette et al., 2014). Cells were washed three times in 1 × PBS. Cells were blocked in 5% BSA in 
PBS for at least 30 minutes. Primary antibodies were diluted in 5% BSA + 0.3% Triton X-100. RBM20 antibody 
(ThermoFisher, Cat#PA5-58068) was used at 1:500, DDX6 (MilliporeSigma, Cat# SAB4200837), and G3BP1 
(SantaCruz Biotechnology, Cat# sc-365338) antibodies were used at 1:200. For actin visualization, phalloidin-
488 (ThermoFisher Scientific, Cat# A12379) in 1x PBS (15 μl of stock phalloidin per 200 μl of PBS) was used 
for 3 hr at room temperature. DNA was visualized via DAPI staining for 30 minutes at room temperature (final 
concentration 1.2 μM). Cells were kept and imaged in 1x PBS. 
 
Structured Illumination Microscopy 
SIM microscopy was performed on a GE Healthcare DeltaVision OMX SR microscope equipped with a 
PLAPON 60xOPSF/1.42 NA objective with a pco.edge 4.2 sCMOS camera at room temperature. Image 
reconstruction was performed using GE softWoRX software. Grant S10 OD021490 
 
Spinning Disk Microscopy 
Spinning disk microscopy was performed on a Nikon Eclipse Ti equipped with a Yokogawa CSU-W1 spinning 
disk head, Andor iXon LifeEMCCD camera, and 100x Plan Apo and 60x Plan Apo objectives. 
 
Co-localization Analysis 
3-dimensional Z-stack spinning disk confocal images of RBM20 and DDX6 were separately binarized using the 
Allen Institute Cell Segmenter (Centrin-2 pipeline for RBM20 and Dots pipeline for DDX6, exact segmentation 
parameters available upon request; https://www.allencell.org/segmenter.html). Segmented channels were then 
max projected and co-localization was measured using the imaged-based MeasureColocalization pipeline in 
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CellProfiler (version 4.0.4) (Carpenter et al., 2006). Measurement of co-localization reflects the Pearson’s 
correlation coefficient (Adler and Parmryd, 2010). 
 
RBM20 localization analysis 
To accurately quantify RBM20 localization, analysis of SIM images was required, as confocal techniques did 
not provide the required resolution (see Figure 2). 3-dimensional Z-stack SIM images of RBM20 and DNA 
(Hoescht stain) were individually binarized using the Surfaces function in Imaris 9.7 (https://imaris.oxinst.com/). 
Two additional RBM20 masks were made using the nuclear mask as a fiducial marker. First, a “Nuclear 
RBM20 mask” was made by assigning all RBM20 within the nucleus a value of, “1”. Second, a, “Cytoplasmic 
RBM20 mask” was made by assigning all RBM20 outside the nuclear mask a value of, “0”. Using these masks, 
the intensity value of RBM20 particles was measured in the nuclear and cytoplasmic compartments, and 
percent localization of nucleus vs cytoplasm was calculated (e.g. percent in compartment divided by total 
signal). Statistical significance was calculated using a student’s T-test.  
 
Western blot 
Protein lysates were obtained with RIPA buffer containing 1x Halt protease inhibitor cocktail (Thermo Fisher 
Scientific). Following clarification of the lysate by centrifugation and assessment of protein concentration by 
BCA assay (Thermo Fisher Scientific), samples were diluted with 3x Blue Protein Loading Dye (New England 
Biolabs) and boiled for 5 minutes. Twenty micrograms of protein were separated via electrophoresis using 4 – 
20% Mini-PROTEAN TGX Precast Protein Gels (Bio-Rad). Proteins were transferred to PVDF membranes and 
blocked in TBS with 0.1% Tween-20 (TBST) and 5% Blotting Grade Buffer (BGB, Bio-Rad). The anti-RBM20 
rabbit polyclonal primary antibody (Abcam, ab233147)) was diluted at 1:1000 in TBST 5% BGB and incubated 
overnight at 4 °C. Membranes were washed three times in TBST for 10 min at room temperature, incubated for 
1 h at room temperature with goat anti-rabbit HRP-conjugated secondary antibody, and washed three times in 
TBST for 10 min. Chemiluminescent reaction was initiated by incubation with SuperSignal West Pico 
Chemiluminescent Substrate (ThermoFisher), and images were acquired using a ChemiDoc Imaging System 
(Bio-Rad) in “high resolution” mode. Before re-probing for the housekeeping protein GAPDH (mouse 
monoclonal [6C5] diluted at 1:5000; Abcam #8245) according to the same protocol but using goat anti-mouse 
HRP-conjugated secondary antibody, membranes were treated with Restore Plus western blot stripping buffer 
(ThermoFisher)for 15 minutes at room temperature, washed three times, and re-blocked. Band intensity was 
calculated by measuring intensity Fiji (Fiji Is Just ImageJ, https://imagej.net/Fiji) and normalized for background 
and GAPDH loading control (Schindelin et al., 2012). 
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FIGURES AND FIGURE LEGENDS 
 
 
Figure 1. Generation and functional characterization of Mutant iPSC-CMs 
A) Targeted genomic region of RBM20. The location of R636 and the 8 nucleotides deleted in 8-bp Del HMZ line 
are highlighted. B) Genomic sequences of the generated RBM20 HTZ and HMZ iPSC lines. C) Genomic 
sequence of the generated RBM20 8-bp Del HMZ line (KO). D) iPSC-CM electrophysiological parameters from 
Multi-electrode Array (MEA) recordings. Color-coded paired replicates represent a biologically independent 
average of 4 technical replicates. E) Representative 3D-engineered heart tissues (3D-EHT) from WT and RBM20 
mutant cell lines. Phase-contrast microscopy, scale bar: 1 mm. The location of flexible and glass-stiffened 
silicone posts is indicated. F) Contractile metrics of 3D-EHTs. Dots represent individual 3D-EHTs from N = 2 for 
WT and N=3 for HTZ, HMZ, and KO 3D-EHTs independent biological replicates. Statistical significance was 
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Figure 2. Intracellular RBM20 localization in RBM20 Mutant iPSC-CMs 
A) Immunofluorescence for RBM20 in WT and RBM20 mutant iPSC-CMs. Spinning disk confocal, scale bar: 5 
μm. B) Structured illumination microscopy of DNA (magenta) and RBM20 (green). Left WT image represents 
X-Y maximum intensity projection, right images represent X-Z 3D projections. Yellow arrowheads indicate 
perinuclear localization of RBM20 in mutant cells. Yellow stars indicate nuclear localization of RBM20. Scale 
bar: 5 μm. C) 3D localization analysis of RBM20 from 3D-SIM images. Magenta bars (left bar above genotype) 
indicate percent nuclear localization, green bars (right bar above genotype) indicate percent cytoplasmic 
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Figure 3. RBM20 mutant protein preferentially binds to the 3′ UTR of novel transcripts 
A) Illustration of the eCLIP strategy for wild-type and R636S HMZ iPSC-CMs. B) Frequency of reproducible 
eCLIP peaks for WT and R636S HMZ iPSC-CMs within coding sequence (cds) exons, introns and UTR regions. 
C) HOMER de novo motif enrichment logos and enrichment p-values for the top ranked RNA-binding protein 
recognition elements defined from the CisBP-RNA database. RBM20-associated motifs are highlighted in red 
and RNA-stabilization associated factors in blue. D) Frequency bar chart of reproducible peaks in R636S HMZ 
eCLIP and the most similar eCLIP profiles from ENCODE (K562 or HepG2 cells), based on correlation to their 
frequency profiles. E) Overlap of R636S peaks in reproducible ENCODE eCLIP peaks, ranked by their 
percentage overlap. One previously described ALS eCLIP profile for the FUS-P525L mutation is included and 
highlighted in red, representing peaks only found in the FUS mutant compared to controls. Blue text indicates 
RBPs with statistically enriched RBM20 motifs-based on HOMER (Supplementary Fig. 4B). F) Gene-set 
enrichment with GO-Elite of genes associated with FUS-P525L and R636S overlapping peaks, for disease 
associated gene-sets (red, DisGeNET), aggregate pathways (green, ToppFun) and Gene Ontology (black).  G) 
Overlap of genes up- or down-regulated by RNA-Seq in R636S iPSC-CMs (HTZ + HMZ) versus RBM20 deletion 
and R636S eCLIP peaks. H) Heatmap of all statistically ranked and organized (MarkerFinder algorithm) RBM20 
R636S or deletion genes in iPSC-CMs by RNA-Seq. Statistically enriched gene-sets (GeneOntology + 
PathwayCommons) are indicated in blue with their associated Fisher’s Exact test p-value and R636S eCLIP 
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Figure 4. RBM20 mutation and knockout impact distinct pathways at the level of alternative splicing 
A) Percentage of alternative splicing events considered differential (LIMMA corrected t-test p<0.1, FDR corrected 
and 𝛅PSI>0.1) for each of the iPSC-CM genotypes versus WT, separated by the predicted event-type (e.g., 
cassette-exon, intron retention) (top). Below, the percentage of splicing events associated with either cassette-
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of exon-level relative expression levels (splicing-index) for two of example significant genes, TTN and CDC14B, 
predicted to be alternatively spliced in R636S HTZ and HMZ cells in a dosage-dependent manner. AltAnalyze 
exon identifiers are shown below. C) Heatmap of the predominant alternative splicing patterns (MarkerFinder) 
for all reasonably detected splicing events (eBayes t-test p<0.05, 𝛅PSI>0.1). The description of each pattern is 
displayed to the left of the heatmap (Incl = exon-inclusion, Excl = exon-exclusion associated splicing events). 
Splicing events with intronic eCLIP peaks in the same gene or that are also observed for the same exon-exon 
junctions as neonatal R636S porcine model (orthologous genome coordinates) are denoted to the right of the 
plot with examples listed. Underlined splicing-event genes indicate prior evidence of RBM20-dependent 
alternative splicing from rat KO studies. D-I) SashimiPlot genome visualization of RBM20-dependent splicing 
events observed in iPSC-CMs, associating with distinct patterns of regulation. Representative samples were 
selected. Specifically, R636S-allele dosage dependent splicing (D), dosage-independent R636S splicing (E), 
R636S but not KO dependent splicing (F), R636S-HTZ-specific events (G), R636S-HMZ-specific events, and 
RBM20-KO specific events (I) among a series of those visualized by SashimiPlot analysis (see Extended Data 
Fig. 5 and S6). Splice-junction read counts are denoted above each curved exon-exon junction line, along with 
the estimated percentage of exon-inclusion. J) Gene-set enrichment analysis (GO-Elite) of splicing-events 
segregated according to the MarkerFinder assigned patterns (panel C). Gene-sets correspond to either Mouse 
Phenotype Ontology or a collection of Pathway databases from ToppCell. * = verified splicing event patterns 
inferred from independently edited iPSC-CMs. ° = verified splicing event from R636S HTZ edited pig hearts. • = 
R636S eCLIP intron bound peak containing. 
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Figure 5. Intracellular localization of RBM20 mutant iPSC-CMs and association with P-bodies 
A) Localization of RBM20 (green) and DDX6 (processing bodies, magenta). High-magnification inserts highlight 
co-localization). Spinning disk confocal, scale bar: 5 μm. B) DDX6/RBM20 co-localization is quantified via 
Pearson′s coefficient of co-localization. Data from N = 3 biological independent experiments. Statistical 
significance was calculated using one-way ANOVA with Dunnett’s multiple comparisons test. C) Structured 
Illumination microscopy of DDX6 (left), RBM20 (middle), and merged channels (DDX6: magenta, RBM20: 
green). White arrows indicate co-localization; yellow asterisk indicates RBM20 not associated with processing 
bodies. Scale bar: 0.5 μm. D) Assessment of stress granules via G3BP1 localization. iPSC-CMs were analyzed 
in basal conditions (e.g., normal media) and in response to stress (1 mM Sodium Arsenate treatment for 1 hour). 
Spinning disk confocal, scale bar: 5 μm. E) Structured illumination microscopy analysis of RBM20 (yellow) and 
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Figure 6. Model of mutant RBM20 differential splicing and P-body impacts in dilated cardiomyopathy. 
Proposed model for the impact of wild-type and mutant RBM20 on nuclear regulation of splicing based on RNA-
Seq and eCLIP data as compared to cytoplasmic role of mutant RBM20 on P-body formation and 3’UTR 
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Extended Data Figure 1. Generation of RBM20 mutant iPSC lines by genome-editing. 
A) Dual Cas9 nickase design to target the WT allele in R636S HTZ iPS cells to generate R636S HMZ cells. 
RBM20 gRNA-2 is specific to the RBM20 WT allele, so that the R636S allele could not be targeted. 
Recombination between the WT allele and the donor oligonucleotide with the R636S and the S635S silent 
mutation resulted in R636S HMZ cells that have the R636S allele and the R636S+SM allele. B) Allele specific 
probe design and concentration to detect the three alleles by ddPCR. To distinguish the R636S+SM allele from 
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ddPCR analysis to simultaneously detect the three alleles. The parental RBM20 R636S HTZ iPS cells, and a 
cell population targeted to generate the R636S HMZ iPS cell line were analyzed with the probes shown in B). 
The R636S+SM allele-positive droplets were observed in the targeted cells as FAM strongly positive population. 
Cell populations with a higher frequency of the R636S+SM allele and a lower frequency of the WT allele were 
enriched to isolate the R636S HMZ iPS cell clone. D) Immunofluorescent staining confirming depletion of RBM20 
in the 8-bp Del HMZ iPSC-CMs. RBM20 (green) and ACTININ (Red) were visualized in WT and the 8-bp Del 
HMZ iPSC-CMs. The nuclei (blue) were stained with DAPI, and the merged images are also shown. Scale bar; 
100 µm. E) Western blot showing loss of RBM20 protein in RBM20 KO iPSC-CMs. F and G) Karyotypes of 
R636S HTZ (E) and HMZ (F) iPS cell clones. Both lines maintained a normal male karyotype. H) Flow cytometry 
demonstrates RBM20 mutant iPSCs successfully differentiate into iPSC-CMs as assessed via cTnT stain 
following sodium lactate purification. 
 
 
Extended Data Figure 2. RBM20 mutant bound transcripts and functional impact.  
A) Graphical overview of the “omics” integrative analysis strategy and analytical approaches to identify 
molecular impacts of RBM20 mutation or deletion. B) Enrichment of RBM20 binding sites among RBPs with 
RBM20-mutant shared eCLIP peaks by HOMER using RNA recognition Elements from the CisBP-RNA 
database. C-D) Gene-set enrichment of analyses with the software ToppFun of genes with reproducible eCLIP 
peaks in wild-type (C) and R636S-HMZ (D) iPSC-CMs. E) MarkerFinder gene expression heatmap from Fig. 5, 
with specific genes noted for minor expression patterns. 
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Extended Data Figure 3. Stage-specific transcriptomic differences in cardiomyocyte differentiation. 
A) The GiWi protocol was used to obtain day 30 differentiated cardiomyocytes which were assessed at day 15 
for negative and normal differentiated samples stained with cTnT by flow-cytometry. B-C) Differentiation 
efficiencies were measured by cTnT staining at (B) day 0 and (C) day 15 cells. D) TaqMan analysis shows the 
sequential progression from iPS cells (POU5F1) into functional CMs (NKX2-5, MYH6 & MYH7). Relative gene 
expression is graphed as a percentage of the maximal expression observed. E) The total number of detected 
genes (protein-coding and ncRNA) expressed with an RPKM > 3 and at least 50 reads/gene at each time-point 
of differentiation. F) Heatmap of all differentially expressed genes (fold>1.5 and empirical Bayes moderated t-
test p<0.05, FDR corrected) for each timepoint for versus day 0, ordered by the software MarkerFinder. G) 
Heatmap of the predominant WikiPathways associated with top-200 time-point specific marker genes, based 
on Z-score enrichment (GO-Elite software). H) Temporal changes in gene expression (log2 fold change) 
across time-points of cardiac differentiation, visualized in the context of prior defined cardiac differentiation 
markers in PathVisio (WikiPathways:WP2406). I) Heatmap of qPCR validation results (delta CT values) of the 
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Extended Data Figure 4. Validation of RBM20-mediated splicing during iPSC-CMs differentiation.  
A) Extent of expressed known and novel exon-exon junctions (at least 5 reads in 3 or more samples) observed 
from all cardiac differentiation RNA-Seq samples. Trans-spliced events are between two adjacent or distant 
genes, proximal splice-sites (SS) are those occurring within 50nt of a known splice site and intronic are those 
occurring >50nt away. B) Genes with novel exons were identified from AltAnalyze and verified by targeted 
amplification (amplicon) and Sanger sequencing. BLAT aligned sequences are derived from the consensus of 
forward and reverse primer amplifications. MESP1 splicing to an unknown (UNK) lncRNA on the reverse 
strand. One confirmed mRNA downstream for this lncRNA is shown in blue (amplicon 3), with a trans-splicing 
isoform produced between MESP1- and this lncRNA in purple (amplicon 2). Two novel N-terminal alternative 
isoforms of the gene WNT5A, with an alternatively excluded exon 2 (amplicon 2) and a novel alternative 
promoter regulated exon (amplicon 3) in green on the reverse strand. C) Heatmap of all differential splicing 
events (dPSI>0.1 and empirical Bayes moderated t-test p<0.05, FDR corrected) for each timepoint for versus 
day 0, ordered by the software MarkerFinder. D) Incidence of alternative splicing for exon-inclusion (top) and 
exon-exclusion for each iPSC-CM differentiation versus day 0, by Percent Spliced-In analysis. H) Heatmap of 

















































Novel - intronic SS
Novel - proximal SS 
Novel - annotated SS  
Annotated junctions 
D03





















Amplicon 2 Amplicon 1
D06






































































































































































































































.CC-BY 4.0 International licenseavailable under a
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprint (whichthis version posted June 7, 2021. ; https://doi.org/10.1101/2021.06.02.446820doi: bioRxiv preprint 
during distinct phases of iPSC-CM commitment. F) SashimiPlots illustrating the temporal regulation of novel 
(GSE1) and known (CAMK2D) RBM20 target exons by alternative splicing. Curved lines indicate splice-
junctions with associated aligned reads. The percentage indicates the amount of relative exon-inclusion. G) 
Comparison of previously identified day 40 cardiac differentiation associated alternative splicing events 
(Salomonis et al., 2009) to similar computed exon-level splicing-index values from iPSC-CM day 30 RNA-Seq. 
Shown are the 41 out of 47 expressed exons that could be comparably mapped to AltAnalyze annotated exons 
are shown. red=positive SI fold (exon-inclusion in hESC), blue=negative SI fold (exon-inclusion in CM), 
grey=disagreeing. H-I) Representative RT-PCR images for novel detected iPSC-CM differentiation splicing 
events, denoting the expected size of each amplicon. Example novel RBM20 target splicing-events, evidenced 
from gene-edited iPSC-CMs, with evidence of differentiation regulation are separately called out in panel I.  J) 
Gene expression level of RBM20 throughout differentiation (blue points), co-visualized with GO-Elite Z-score 
enrichment results for alternatively spliced exons in differentiation (versus day 0) relative to RBM20-mutant 
patient (dilated cardiomyopathy) versus control splicing events.  
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Extended Data Figure 5. Visualization and verification of specific iPSC-CM RBM20 splicing events.  
A) Heatmap of shared splicing patterns observed in independently RBM20 edited iPSC-CM lines (dPSI vs. 
matched control lines). The R636S HTZ mutation was edited into the WTB line, whereas independently edited 
HMZ iPSC-CMs (including HMZ S635 frame-shift), were reanalyzed from Briganti et al. B-F) SashimiPlots of 
example splicing events from Fig. 4C, associated with the indicated patterns of unique or shared regulation.  * = 
verified splicing event patterns inferred from the independently edited iPSC-CMs. ° = verified splicing event from 
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Extended Data Figure 6. Porcine 16-week neonatal heart R636S-mutant regulated splicing events.  
A) Heatmap of the predominant patterns of alternative splicing in the pig heart for significantly differential events 
(dPSI>0.1 and empirical Bayes moderated t-test p<=0.05). See Fig. 4C for a detailed description of the 
overlapping eCLIP and human-conserved splicing event predictions. Genes for conserved hiPS-CM RBM20 
mutant splicing events are displayed to the right.  B-D) Example SashimiPlots of R636S-regulated splicing events 
in pigs that correspond to conserved and non-conserved events. Specifically, R636S events with observed 
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Extended Data Figure 7. Impact of RBM20 mutation on circular RNA and alternative polyadenylation.  
A) Venn diagram of differentially regulated circRNAs, comparing R636S mutants or RBM20 KO to wild-type 
RiboMinus RNA-Seq sample groups (EdgeR p<0.1). circRNA genes with evidenced eCLIP peak genomic 
overlaps are denoted, based on the eCLIP source (mutant or wild-type). The number of circRNAs with eCLIP 
overlaps are denoted in each Venn circle (purple = R636S eCLIP, gold = WT eCLIP). B) Venn diagram of 
differentially expressed circRNAs that also have genomic overlapping alternative splicing events for the indicated 
sample-group comparisons. Such events represent coordinately regulated circRNAs and alternative-splicing 
events. The majority of such events are associated with a single gene (TTN), that are associated with multiple 
independent splicing events. C) Heatmap of alternative polyadenylation (APA) 3′ UTRs, organized using the 
software MarkerFinder into the predominant patterns of regulation. Gene-set enrichment results (GO-Elite) for 
each cluster are shown to the left of the heatmap (ToppFun pathway collection). Note that for each APA event, 
at least one reciprocal redundant APA event may also be reported (e.g., short form, long form). Any reproducible 
eCLIP peaks within the gene body of APA impacted genes are shown are indicated to the right of the heatmap. 
D) Venn diagram of genes with APA events significantly up-regulated in RBM20 KO versus R636S HMZ iPSC-
CMs (relative APA ratio differences > 0.1 and empirical Bayes moderated t-test p<0.05) and genes with observed 
R636S eCLIP peaks. E) Gene Ontology enrichment analysis (GO-Elite) for the 534 overlapping RBM20 KO and 
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Extended Data Video 1 
WT iPSC-CMs beat spontaneously on Multi-electrode Array (MEA) plates. Black structures are electrodes. 
Video played at real time, 19.9 fps. Video length = 10 seconds, magnification = 20x. Brightfield microscopy. 
 
Extended Data Video 2 
3D-EHTs cast from iPSC-CMs spontaneously beat in culture. Flexible post (left) is moved during contraction 
while stiff glass post (right) remains motionless. Video played at real time, 66 fps. Video length = 5 seconds, 
magnification = 2x. Brightfield microscopy. 
 
Extended Data Video 3 
3D-EHTs cast from iPSC-CMs can be electrically paced. Tissue has been paced at 2 Hz. Video is played at 
real time, 66.6 fps. Video length = 3 seconds, magnification = 2x. Brightfield microscopy. 
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